Chemical Business Newsbase articles from April 2011, page 2

Chemical Business Newsbase archives from April 2011

Regulations Commission Implementing Regulation (EU) No 388/2011 of 19 Apr 2011 concerning the authorisation of maduramicin ammonium alpha as a feed additive for chickens for fattening (holder of authorisation Alpharma (Belgium) BVBA) and amending Regulati.
April 20, 2011... The European Commission, having regard to the Treaty on the Functioning of the European Union, having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 Sep 2003 on additives for use in animal nutrition...

Commission Implementing Regulation (EU) No 389/2011 of 19 Apr 2011 concerning the authorisation of an enzyme preparation of endo-1,4-beta-xylanase, subtilisin and alpha-amylase as feed additive for laying hens (holder of authorisation Danisco Animal Nutri.
April 20, 2011... The European Commission, having regard to the Treaty on the Functioning of the European Union, having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 Sep 2003 on additives for use in animal nutrition (...

Commission Implementing Directive 2011/50/EU of 19 Apr 2011 amending Council Directive 91/414/EEC to include carbetamide as active substance and amending Commission Decision 2008/934/EC.
April 20, 2011... The European Commission, having regard to the Treaty on the Functioning of the European Union, having regard to Council Directive 91/414/EEC of 15 Jul 1991 concerning the placing of plant protection products on the market (1), and in particular...

Omnova wall coverings compliant with European Union requirements, carry CE mark.
April 20, 2011... OMNOVA Solutions' Avant, Bolta, Essex, Genon, Scion and Tower commercial wall coverings have been deemed compliant by the European Union and are certified to carry the CE mark, permitting their sale in all member countries. As of Jan 2011, all...

FDA approves Roche's HPV test for identifying women at highest risk for cervical cancer.
April 20, 2011... On 20 Apr 2011 Roche announced that the US Food and Drug Administration has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more...

UPM and Vertaris to promote sustainable release liner recycling.
April 20, 2011... UPM and French company Vertaris have teamed up to develop a sustainable release liner recycling concept in Europe. Release liners are the siliconised backing paper that are an essential part of self-adhesive labelstock until the printed label is...

Astellas launches orally disintegrating tablet Vesicare OD in Japan.
April 20, 2011... On 20 Apr 2011, Astellas Pharma Inc announced that a new dosage form of Vesicare (generic name: solifenacin succinate), the orally disintegrating tablet "Vesicare OD Tablet 2.5mg/5mg" for an additional formulation of the overactive bladder (OAB)...

Sherwin-Williams declares dividend; Richard K. Smucker Elected Lead Director.
April 20, 2011... On 20 Apr 2011, the Board of Directors of The Sherwin-Williams Co announced a regular quarterly dividend of $0.365 per common share, payable on 3 Jun 2011, to shareholders of record on 20 May 2011. In addition, the Board of Directors elected...

Four missing after Czech explosives plant blast.
April 20, 2011... An official says a huge nitroglycerine explosion has occurred at a factory in the Czech Republic and that four people are missing. The blast on 20 Apr 2011 destroyed a building at the plant, which makes explosives for customers including the...

Vedanta picks up GBP 920 M stake in Cairn India.
April 20, 2011... Vedanta Resources has snapped up a 10.4% stake in Cairn India for about GBP 920 M, in a signal of its determination to take control of the oil company, even as political uncertainty hangs over the deal. The miner, which is trying to make its...

Xstrata investors urged to reject Glencore names.
April 20, 2011... Shareholders at Xstrata's upcoming annual meeting should vote against the three non-executive directors proposed by Glencore, the Swiss commodities trader, a leading advisory group said on 19 Apr 2011. Pirc, which advises pension funds on how...

MYK Laticrete to set up third plant in Tamil Nadu.
April 20, 2011... MYK Laticrete, a 50:50 joint venture between the US-based Laticrete International and the Hyderabad, India based MYK Group, plan to set up its third facility in Tamil Nadu by end 2011 to manufacture building products which includes, adhesives,...

US drug recall not to have big financial impact on Lupin: Adulterated presence of foreign tablets in hypertension drug Lisinopril.
April 20, 2011... Pharma firm Lupin has stated that its recent voluntary recall from the US market of its hypertension drug Lisinopril in the US will not have any major impact financially. The company recalled one batch of Lisinopril 30 mg tablets in 100s bottles...

Now, a Champions Blue from Nerolac.
April 20, 2011... Kansai Nerolac Paints has introduced a new range of lead free premium exterior emulsions called 'Nerolac Excel' and 'Excel Total'. The company has congratulated the Indian Cricket team (on winning the world cup) and has dedicated a special shade...

Rajoo Engineers inks pact with Italian firm for pipes.
April 20, 2011... Rajoo Engineers of India, which is known for manufacturing of blown film and plastic extrusions has announced that it has formed a joint venture with Bausano & Figli Spa of Italy. The joint venture company Rajoo Bausano Extrusion will...

PRANA Biotechnology accelerates PBT2 commercial development.
April 20, 2011... Prana Biotechnology announced its business strategy to accelerate development of its lead asset, PBT2. The strategy, that now includes Huntington's Disease (HD), should enable Prana to target market approval for PBT2 several years sooner than...

Galapagos NV delivers validated oncology targets to Janssen Pharmaceutica NV.
April 20, 2011... Galapagos NV announced that its BioFocus service division has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica NV (Janssen). As Per the agreement,...

GW Pharmaceuticals release: US patent granted for Sativex in cancer pain.
April 20, 2011... GW Pharmaceuticals plc announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent which protects the use of Sativex as a treatment for cancer pain. The patent, entitled 'Pharmaceutical Compositions...

NicOx SA (COX PA) pulls drug application for Beprana (naproxcinod).
April 20, 2011... NicOx SA announced its decision to withdraw the Marketing Authorization Application (MAA) for its osteoarthritis candidate naproxcinod from the centralized procedure in Europe. NicOx submitted the naproxcinod MAA to the European Medicines Agency...

Gilead Sciences Inc, MicroDose Therapeutx ink licence deal for MDT 637.
April 20, 2011... Gilead Sciences has obtained a licence from MicroDose Therapeutx to an inhalable small molecule drug for respiratory syncytial virus. Foster City-based Gilead agreed to make an upfront cash payment, research funding, milestone payments, and...

Icon and Acronet sign alliance agreement in Japan.
April 20, 2011... Icon plc and Acronet Corp have announced they have signed an alliance agreement. Through the agreement, Icon and Acronet will collaborate to offer global and Japanese pharmaceutical clients a full range of clinical development capabilities to...

Actient Pharmaceuticals LLC announces acquisition of Striant (testosterone buccal system) from Columbia Laboratories Inc.
April 20, 2011... Actient Pharmaceuticals LLC (Actient) has announced that it has acquired the US rights to Striant (testosterone buccal system) from Columbia Laboratories Inc. Striant utilises a novel mucoadhesive technology that allows for oral administration...

Celera provides update on recent scientific findings on KIF6 and PMA application.
April 20, 2011... Celera Corp has provided an update on recent scientific findings pertaining to the KIF6 gene variant and its pre-market approval application (PMA) with the US Food and Drug Administration (FDA) for its KIF6 Genotyping Assay. In nine previously...

Wedgewood Pharmacy will compound cytarabine, a life-saving leukaemia drug in critically short-supply.
April 20, 2011... Wedgewood Pharmacy will compound Cytarabine 20 mg/ml injection solution, which is in critical short supply due to increased demand and manufacturing delays. Cytarabine often is prescribed to treat leukaemia. Healthcare facilities across the US...

Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership.
April 20, 2011... Shanghai Pharmaceutical Co Ltd (Shanghai Pharmaceutical) and Pfizer Inc have announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China. The potential partnership is...

Five-nation breast cancer study chooses Agilent Technologies microarrays as primary genomic screening tool.
April 20, 2011... Agilent Technologies Inc (Agilent) announced that the US-Latin American Cancer Research Network (US-LACRN) has selected Agilent Gene Expression microarrays and associated instruments for a major study of breast cancer in five Latin American...

NanoBio announces development of nasal vaccine for the prevention of urinary tract infections in collaboration with the University of Michigan.
April 20, 2011... NanoBio Corp announced a licensing agreement with the University of Michigan that provides NanoBio with rights to an antigen that has been shown to prevent urinary tract infections (UTIs) following intranasal vaccination. Through the agreement,...

St Jude Medical announces FDA approval of Trifecta valve.
April 20, 2011... St Jude Medical Inc has received US Food and Drug Administration (FDA) approval for its Trifecta valve. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy...

Vince & Associates Clinical Research multi-million dollar clinical pharmacology expansion fulfills the needs of accelerated early phase clinical development.
April 20, 2011... Vince & Associates Clinical Research announces the opening of their multi-million dollar, 90-bed Clinical Pharmacology Research Unit. This premier research facility is a culmination of years of planning and design by a team of over 50...

Biomagnetics and Los Alamos National Laboratory agreement produce validated assay for tuberculosis biomarker - company prepares for deliveries.
April 20, 2011... Biomagnetics Diagnostics Corp has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organisations. To date for the...

Aduro BioTech completes $19.25 M Series B financing.
April 20, 2011... Aduro BioTech has completed its Series B equity financing from a combination of current investors and Morningside Ventures, bringing the total capital secured in this round to $19.25 M. Aduro BioTech previously reported results from a Phase I...

Ligand partner Prism Pharmaceuticals to be acquired by Baxter.
April 20, 2011... Ligand Pharmaceuticals Inc (Ligand) announced that its partner Prism Pharmaceuticals (Prism) has entered into a definitive agreement to be acquired by Baxter International Inc (Baxter). Prism recently received FDA approval for Nexterone, an...

CytRx increases clinical sites to 15 in tamibarotene Phase IIb clinical trial in 1st line non-small-cell lung cancer to expedite patient recruitment.
April 20, 2011... CytRx Corp has expanded enrolment to 15 clinical sites in its Phase IIb clinical trial with tamibarotene in combination with chemotherapeutical agents for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The large...

Gilead and MicroDose Therapeutx announce licence and collaboration agreement to develop MDT-637 for treatment of respiratory syncytial virus.
April 20, 2011... Gilead Sciences Inc and MicroDose Therapeutx Inc have entered into an exclusive worldwide licence and collaboration agreement for the development and commercialisation of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor...

Ariad announces three exclusive out-licence agreements to develop and commercialize its ARGENT cell-signalling regulation technology.
April 20, 2011... Ariad Pharmaceuticals Inc (Ariad) announced execution of three exclusive out-licence agreements for separate aspects of its ARGENT cell-signaling regulation technology. The licenses to these non-core assets provide Ariad with a combination of...

Salix Pharmaceuticals secures additional intellectual property relating to Rifaximin.
April 20, 2011... Salix Pharmaceuticals Ltd (Salix) has announced that the US Patent and Trademark Office has issued three patents relating to rifaximin. US Patent number 7,928,115 (the '115 patent), which issued 19 Apr 2011, provides protection to methods of...

The Ludwig Institute and Pro-Pharmaceuticals discover that Davanat enhances the ability of anti-tumour T lymphocytes to kill tumour cells.
April 20, 2011... Pro-Pharmaceuticals Inc has announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (Davanat) to enhance the ability of tumour-specific T-lymphocytes to kill tumour cells. The findings...

AE Biofuels subsidiary receives $1.88 M Advanced Biofuels Grant from California Energy Commission.
April 20, 2011... AE Biofuels Inc has announced its wholly-owned advanced ethanol subsidiary AE Advanced Fuels Keyes Inc (AE Keyes), has been awarded a $1.88 M matching grant from the California Energy Commission (CEC) to accelerate the commercial implementation...

Universal Bacteria Specialist Oilfield biocide product receives EPA Registration.
April 20, 2011... Universal Bacteria Specialist has announced that the US Environmental Protection Agency (EPA) has registered its ECAT-O&G biocide as an environmentally friendly alternative for eliminating bacteria from the hydraulic fracturing of wells....

Exterra announces the acquisition of a private oil & gas company.
April 20, 2011... Exterra Energy Inc (Exterra) announced that they are 'gaining a partner' with the acquisition of Resonance Energy LLC (Resonance), a closely held private oil and gas limited liability company headquartered in Florida. Resonance has signed a PSA...

Research and Markets: Belgium Oil and Gas Report 1Q 2011- oil imports are growing steadily.(Report)
April 20, 2011... Research and Markets has announced the addition of the 'Belgium Oil and Gas Report 1Q 2011' report to their offering. The new Belgium Oil & Gas Report from BMI forecasts that the country will account for 6.08% of developed European regional...

3M acquires Original Wraps Inc.
April 20, 2011... On 20 Apr 2011, 3M announced it has acquired Original Wraps Inc, a Golden, Colorado-based company specializing in the creative business development, technology and design of personalization platforms for vehicles and vehicle accessories. Terms...

Acron Group releases 1Q 2011 operating results.(Financial report)
April 20, 2011... For its 1Q 2011, Acron Group (Acron, Dorogobuzh, Hongri Acron) has published consolidated production data: ammonia 464,200 tonnes (438,700 for its 1q 2010), nitrogen fertilisers 635,900 tonnes (571,100 tonnes), complex fertilisers 688,400 tonnes...

Chronic hepatitis C treatment, Pegasys, designated for priority review by Ministry of Health, Labour and Welfare for the indication of chronic hepatitis B.
April 20, 2011... On 20 Apr 2011, Chugai Pharmaceutical Co Ltd announced that on 11 Apr 2011, the Japanese Ministry of Health, Labour and Welfare designated Pegasys (peginterferon alfa-2a, genetic recombination), a treatment for chronic hepatitis C (CHC), as a...

Danisco launches targeted probiotic solutions for the whole family.
April 20, 2011... HOWARU Balance supplements the digestive and immune health of young to old. Operating at the forefront of the probiotic revolution, Danisco brings digestive and immune health benefits to the whole family with HOWARU Balance, a new series of...

CSN accepts Rio Tinto offer for Riversdale.
April 20, 2011... Rio Tinto Jersey Holdings 2010 Ltd (RTJ), a wholly-owned subsidiary of the Rio Tinto Group, has received acceptances to its takeover offer (Offer) for Riversdale Mining Ltd (Riversdale) from CSN Europe Lda (CSN) in respect of CSN's entire 19.35%...

New and generic drug approvals: Nafcillin Injection, App Pharms.
April 20, 2011... On 20 Apr 2011, the US Food and Drug Administration announced approval of ANDA 090005 for Nafcillin Injection. The product contains nafcillin at 10g, is manufactured by App Pharms, and is prescription only. There are no therapeutic equivalents.

New and generic drug approvals: Dextromethorphan Polistirex Extended Release Oral Suspension, Tris Pharma.
April 20, 2011... On 20 Apr 2011, the US Food and Drug Administration announced the tentative approval of ANDA 091135 for Dextromethorphan Polistirex Extended Release Oral Suspension. The product contains dextromethorphan polistirex at 30mg/5ml and is...

New and generic drug approvals: Donepezil Hydrochloride Oral Tablet, Wockhardt.
April 20, 2011... On 20 Apr 2011, the US Food and Drug Administration announced the tentative approval of ANDA 091267 for Donepezil Hydrochloride Oral Tablet. The product contains donepezil hydrochloride at 5mg or 10mg and is manufactured by Wockhardt. There are...

New and generic drug approvals: Hydrocodone Bitartrate and Homatropine Methylbromide Oral Tablet, Novel Labs.
April 20, 2011... On 20 Apr 2011, the US Food and Drug Administration announced approval of ANDA 091528 for Hydrocodone Bitartrate and Homatropine Methylbromide Oral Tablet. The product contains hydrocodone bitartrate at 5mg and homatropine methylbromide at...

New and generic drug approvals: Quinapril Hydrochloride and Hydrochlorothiazide Oral Tablet, Invagen Pharms.
April 20, 2011... On 20 Apr 2011, the US Food and Drug Administration announced approval of NDA 201356 for Quinapril Hydrochloride and Hydrochlorothiazide Oral Tablet. The product contains quinapril hydrochloride at 10mg or 20mg and hydrochlorothiazide at 12.5mg...

FDA warns companies to stop making MRSA claims for over-the-counter products.
April 20, 2011... On 20 Apr 2011, the US Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant...

MediGene AG and Triton Pharma sign partnership agreement for the commercialization of Veregen in Canada.
April 19, 2011... MediGene AG has signed an exclusive licence and supply agreement with the Canadian company Triton Pharma Inc (Triton) for the supply and commercialization of Veregen ointment for the treatment of genital warts in Canada. Triton will be...

4-Antibody AG meets first milestone in Boehringer Ingelheim Corp collaboration.
April 19, 2011... 4-Antibody AG has achieved the successful completion of a first milestone in its ongoing collaboration with Boehringer Ingelheim. 4-Antibody's first R&D collaboration with a major pharma partner, Boehringer Ingelheim, commenced in early 2010...

Crystallics-a new company spinout with a long history in pharmaceutical development.
April 19, 2011... Avantium Pharma BV has been spun out from Avantium Holding BV in a management buy-out to create Crystallics. The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for...

Vectura Group plc release: Phase III data show NVA237 significantly improves lung function with good safety profile in COPD patients.
April 19, 2011... Vectura Group plc (Vectura) has announced that NVA237, a long-acting muscarinic antagonist (LAMA) being investigated as a once daily treatment for chronic obstructive pulmonary disease (COPD), achieved its primary endpoint in a Phase III study....

Aoxing Pharmaceutical Co Inc completes technology transfer in joint venture with Macfarlan Smith Ltd.
April 19, 2011... Aoxing Pharmaceutical Co Inc (Aoxing) has announced that Hebei Aoxing API Pharmaceutical Co Ltd (Hebei Aoxing), the joint venture between Aoxing Pharma and Macfarlan Smith Ltd (Macfarlan), has succeeded in adopting advanced process technology...

Lonza Inc and Organobalance enter global licence agreement to develop and market unique probiotic, lactobacillus anti-H pylori.
April 19, 2011... Lonza and Organobalance announced the signing of a worldwide exclusive licence agreement in which Lonza will develop, produce and commercialize products containing a probiotic Lactobacillus strain. Developed by Organobalance GmbH, the probiotic...

Evotec AG completes acquisition of Kinaxo Biotechnologies.
April 19, 2011... Evotec AG has completed the acquisition of Kinaxo Biotechnologies GmbH (Kinaxo), a privately held drug discovery alliance company supporting the development of targeted drugs. As a result of the transaction, first announced on 9 Feb 2011, Kinaxo...

Lead Discovery Center and Bayer Schering Pharma enter into licence agreement covering a novel pharmaceutical lead structure.
April 19, 2011... The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a...

Baxter International Inc to acquire Prism Pharmaceuticals Inc for $338 M.
April 19, 2011... Baxter International Inc (Baxter) has entered into a definitive agreement to acquire Prism Pharmaceuticals Inc (Prism), a speciality pharmaceutical company based in King of Prussia, PA. Prism has developed and received US Food and Drug...

SciClone Pharmaceuticals Inc buys China-based NovaMed Pharmaceuticals Inc for as much as $105 M.
April 19, 2011... SciClone Pharmaceuticals Inc (SciClone) has announced that it has acquired NovaMed Pharmaceuticals Inc, (NovaMed) a China-based speciality pharmaceutical company. The acquisition brings additional broad sales and marketing, as well as regulatory...

FDA approves Rituxan plus a steroid for use in severe forms of vasculitis.
April 19, 2011... Genentech, a member of the Roche Group and Biogen Idec announced that the US Food and Drug Administration (FDA) approved Rituxan (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG)...

Covidien supports FDA on long-acting opioid REMS.
April 19, 2011... Covidien supports the US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) for an important class of pain medications. FDA sent letters to sponsors of long-acting and extended release opioid medications requiring a...

AB Science: Masitinib as an adjunct therapy for Alzheimer's disease.
April 19, 2011... AB Science SA announces the publication of results from the first human Phase II study of masitinib carried-out in the treatment of Alzheimer's disease. Entitled, 'Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a...

Avita Medical expands sales and marketing operations in Europe.
April 19, 2011... Avita Medical Ltd (Avita), has expanded its sales and marketing operations into three new countries: Russia, The Netherlands and Portugal. The Company has previously established commercial operations in Australia, France, Germany and the United...

Adamis completes acquisition of a technology for a potential universal cancer vaccine.
April 19, 2011... Adamis Pharmaceuticals Corp (Adamis) announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California. The patent comprises 'Composition and Method for Inducing and...

Ophthalmologists report significant changes in prescribing among primary open angle glaucoma patients as Pfizer's Xalatan goes generic, according to a recent report from BioTrends.
April 19, 2011... The impact of the genericization of Pfizer's Xalatan at the end of Mar 2011 is reflected in changes to both current and anticipated ophthalmologist prescribing behaviour for primary open angle glaucoma patients. Among pharmacologically-treated...

Biomagnetics begins receiving funding from Biotech Development Partners.
April 19, 2011... Biomagnetics Diagnostics Corp (Biomagnetics) has announced that it has begun receiving funds from a biotech-oriented investment group called Biotech Development Partners LLC. The funds invested by this experienced group of biotech and technology...

Medtronic introduces the Marrowmax Bone Marrow Aspiration Needle Kit.
April 19, 2011... Expanding its leading bone grafting portfolio, Medtronic Inc has announced the US launch of the Marrowmax Bone Marrow Aspiration Needle Kit. The Marrowmax Bone Marrow Aspiration Needle Kit provides a simple technique for aspirating marrow from...

Vicept Therapeutics announces positive results from a second Phase II study of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea).(Report)
April 19, 2011... Vicept Therapeutics Inc (Vicept) has announced positive results from a second Phase II clinical trial evaluating the dose-response relationship of two concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea...

Forest Laboratories and Blue Ash Therapeutics enter into asset purchase agreement for Azimilide, a novel Phase III antiarrhythmic agent.
April 19, 2011... Forest Laboratories Inc has announced that its wholly-owned subsidiary Forest Laboratories Holdings Ltd (Forest) and Blue Ash Therapeutics LLC (Blue Ash) have entered into an asset purchase agreement, pursuant to which Forest Laboratories has...

Ambry Genetics adds certification of Roche NimbleGen CGH, DNA Methylation, Gene Expression, and ChIP-chip to service portfolio.
April 19, 2011... Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen Comparative Genomic Hybridization (CGH), Chromatin...

Acorda Therapeutics announces allowance of US Patent Application for Ampyra (dalfampridine) covering methods of use for improving walking in multiple sclerosis.
April 19, 2011... Acorda Therapeutics Inc announced that the US Patent and Trademark Office (USPTO) have allowed US Patent Application No 11/010,828 entitled 'Sustained Release Aminopyridine Composition.' The claims of the patent application relate to methods to...

MedPro Safety Products and Greiner Bio-One GmbH announce market release of Vacuette premium safety needle system tube-Touch.
April 19, 2011... MedPro Safety Products Inc and its product partner Greiner Bio-One GmbH, jointly announced the market release of the Vacuette PREMIUM Safety Needle System Tube-Touch. The patented technology offers healthcare professionals the safety of a blood...

Genmab and Seattle Genetics expand antibody-drug conjugate collaboration.
April 19, 2011... Genmab A/S and Seattle Genetics Inc have entered into a second antibody-drug conjugate (ADC) research collaboration agreement. Under the new agreement, Genmab has rights to utilize Seattle Genetics' ADC technology with HuMax-CD74, an antibody in...

Biogen Idec receives positive opinion from the CHMP and authorisation from Health Canada on Avonex Pen.
April 19, 2011... Biogen Idec announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Avonex Pen for patients with relapsing multiple sclerosis (MS) and...

Crosstex declares increase in quarterly distribution and dividend payable 13 May 2011.
April 19, 2011... The Crosstex Energy companies have announced the declaration of the quarterly distribution for Crosstex Energy LP and the quarterly dividend for Crosstex Energy Inc from 1Q 2011. The quarterly distribution on the partnership's common and...

Avidan Management commissions US' largest rooftop solar system in New Jersey, using high-performance SolarWorld panels.
April 19, 2011... Avidan Management (Avidan), joined with regional officials to announce completion of US' largest roof-mounted solar panel system. The 4.26 MW system, employing 17,745 high-performance SolarWorld solar panels, will generate clean, renewable...

Ameresco and the City of Dallas unveil innovative wastewater biogas-to-energy facility.
April 19, 2011... Ameresco Inc and City of Dallas Water Utilities (DWU) have announced the completion of an innovative biogas energy recovery facility. During a tour of the facility, Ameresco executives commemorated the 4.3 MW biogas capture and refining...

Renewable Fuel Standard provides market space and predictable price for advanced biofuels.
April 19, 2011... The federal Renewable Fuel Standard (RFS) provides the stable market support and pricing system necessary to attract private investment to the development of advanced biofuels, according to a new policy white paper published by the Biotechnology...

Chevron starts operations of 1 MW CPV solar field in Northern New Mexico.
April 19, 2011... Chevron Mining Inc (Chevron) has announced the start of one of the country's largest concentrating photovoltaic solar facilities. The installation, located on the tailing site of Chevron's molybdenum mine in Questa, NM, will demonstrate and...

Commission Implementing Directive 2011/49/EU of 18 Apr 2011 amending Council Directive 91/414/EEC to include pencycuron as active substance and amending Commission Decision 2008/934/EC.
April 19, 2011... Adopted on 18 Apr 2011. The European Commission, having regard to the Treaty on the Functioning of the European Union, having regard to Council Directive 91/414/EEC of 15 Jul 1991 concerning the placing of plant protection products on the...

Proposal for a Council Regulation imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of sodium gluconate originating in the People's Republic of China.
April 19, 2011... This proposal concerns the application of Council Regulation (EC) No 1225/2009 of 30 Nov 2009 on protection against dumped imports from countries not members of the European Community('the basic Regulation') in the proceeding concerning imports...